MX385717B - Regimen de dosificacion para el tratamiento de exacerbaciones agudas de enfermedad pulmonar obstructiva cronica. - Google Patents
Regimen de dosificacion para el tratamiento de exacerbaciones agudas de enfermedad pulmonar obstructiva cronica.Info
- Publication number
- MX385717B MX385717B MX2018010782A MX2018010782A MX385717B MX 385717 B MX385717 B MX 385717B MX 2018010782 A MX2018010782 A MX 2018010782A MX 2018010782 A MX2018010782 A MX 2018010782A MX 385717 B MX385717 B MX 385717B
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- pulmonary disease
- chronic obstructive
- obstructive pulmonary
- dosage regimen
- Prior art date
Links
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 title abstract 2
- 230000001154 acute effect Effects 0.000 title 1
- VGUSQKZDZHAAEE-UHFFFAOYSA-N 3-[5-amino-4-(3-cyanobenzoyl)pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C=1N)N=CC=1C(=O)C1=CC=CC(C#N)=C1 VGUSQKZDZHAAEE-UHFFFAOYSA-N 0.000 abstract 1
- 230000009798 acute exacerbation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/GB2016/050636 WO2017153702A1 (en) | 2016-03-08 | 2016-03-08 | Dosage regimen for the treatment of acute exacerbations of chronic obstructive pulmonary disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018010782A MX2018010782A (es) | 2019-01-10 |
| MX385717B true MX385717B (es) | 2025-03-18 |
Family
ID=55586330
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018010782A MX385717B (es) | 2016-03-08 | 2016-03-08 | Regimen de dosificacion para el tratamiento de exacerbaciones agudas de enfermedad pulmonar obstructiva cronica. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10603306B2 (enExample) |
| JP (1) | JP6741774B2 (enExample) |
| KR (2) | KR20180118667A (enExample) |
| AU (1) | AU2016397047B2 (enExample) |
| BR (1) | BR112018067454A2 (enExample) |
| CA (1) | CA3016488C (enExample) |
| MX (1) | MX385717B (enExample) |
| RU (1) | RU2713203C1 (enExample) |
| WO (1) | WO2017153702A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX385717B (es) * | 2016-03-08 | 2025-03-18 | Mereo Biopharma 1 Ltd | Regimen de dosificacion para el tratamiento de exacerbaciones agudas de enfermedad pulmonar obstructiva cronica. |
| GB201612240D0 (en) | 2016-07-14 | 2016-08-31 | Mereo Biopharma 1 Ltd | Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide |
| GB201612238D0 (en) | 2016-07-14 | 2016-08-31 | Mereo Biopharma 1 Ltd | Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-Yl]-n-cyclopropyl-4-methylbenzamide |
| EP3845228A1 (en) | 2017-12-11 | 2021-07-07 | Mereo BioPharma 1 Limited | Use of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide in the prevention or reduction of acute exacerbations of chronic obstructive pulmonary disease |
| JP7280627B2 (ja) * | 2017-12-11 | 2023-05-24 | メレオ バイオファーマ １ リミテッド | 慢性閉塞性肺疾患の急性増悪の処置における３－［５－アミノ－４－（３－シアノベンゾイル）－ピラゾール－１－イル］－ｎ－シクロプロピル－４－メチルベンズアミドの使用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9501841D0 (en) | 1995-01-31 | 1995-03-22 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
| US6598603B1 (en) * | 1997-12-31 | 2003-07-29 | Astra Aktiebolag | Method for treating respiratory diseases |
| CN1832928B (zh) | 2003-06-26 | 2012-07-04 | 诺瓦提斯公司 | 以5元杂环为基础的p38激酶抑制剂 |
| TWI439284B (zh) | 2004-04-09 | 2014-06-01 | Abbvie Biotechnology Ltd | 用於治療ＴＮＦα相關失調症之多重可變劑量療法 |
| GB0409703D0 (en) | 2004-04-30 | 2004-06-02 | Vectura Ltd | Pharmaceutical compositions |
| US20050277602A1 (en) | 2004-05-21 | 2005-12-15 | Grunstein Michael M | Methods employing agonists of P38 map kinase for the treatment of asthma |
| US20090270350A1 (en) | 2006-02-10 | 2009-10-29 | Pfizer Inc. | Pyridinone Pyrazole Urea and Pyrimidinone Pyrazole Urea Derivatives |
| GB0603684D0 (en) * | 2006-02-23 | 2006-04-05 | Novartis Ag | Organic compounds |
| LT2827860T (lt) * | 2012-03-20 | 2016-12-12 | Mereo Biopharma 1 Limited | Pirazolo darinio panaudojimas stiprių lėtinės obstrukcinės plaučių ligos paūmėjimų gydymui |
| MX385717B (es) * | 2016-03-08 | 2025-03-18 | Mereo Biopharma 1 Ltd | Regimen de dosificacion para el tratamiento de exacerbaciones agudas de enfermedad pulmonar obstructiva cronica. |
| KR20180119597A (ko) * | 2016-03-08 | 2018-11-02 | 메레오 바이오파마 1 리미티드 | 염증 상태의 급성 악화의 치료를 위한 투약법 |
-
2016
- 2016-03-08 MX MX2018010782A patent/MX385717B/es unknown
- 2016-03-08 JP JP2018547431A patent/JP6741774B2/ja active Active
- 2016-03-08 KR KR1020187026084A patent/KR20180118667A/ko not_active Ceased
- 2016-03-08 KR KR1020247020223A patent/KR102762199B1/ko active Active
- 2016-03-08 RU RU2018132047A patent/RU2713203C1/ru active
- 2016-03-08 BR BR112018067454A patent/BR112018067454A2/pt not_active Application Discontinuation
- 2016-03-08 US US16/082,765 patent/US10603306B2/en active Active
- 2016-03-08 CA CA3016488A patent/CA3016488C/en active Active
- 2016-03-08 WO PCT/GB2016/050636 patent/WO2017153702A1/en not_active Ceased
- 2016-03-08 AU AU2016397047A patent/AU2016397047B2/en active Active
-
2020
- 2020-02-18 US US16/793,922 patent/US11129810B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112018067454A2 (pt) | 2019-01-15 |
| US20190060279A1 (en) | 2019-02-28 |
| CA3016488C (en) | 2023-04-11 |
| JP2019507786A (ja) | 2019-03-22 |
| US20200281896A1 (en) | 2020-09-10 |
| WO2017153702A1 (en) | 2017-09-14 |
| KR20240101698A (ko) | 2024-07-02 |
| MX2018010782A (es) | 2019-01-10 |
| US11129810B2 (en) | 2021-09-28 |
| AU2016397047A1 (en) | 2018-09-06 |
| CA3016488A1 (en) | 2017-09-14 |
| AU2016397047B2 (en) | 2022-04-07 |
| US10603306B2 (en) | 2020-03-31 |
| KR20180118667A (ko) | 2018-10-31 |
| KR102762199B1 (ko) | 2025-02-07 |
| JP6741774B2 (ja) | 2020-08-19 |
| RU2713203C1 (ru) | 2020-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL264210A (en) | High-strength oral cannabinoid dosage forms | |
| IL275484A (en) | W/O/W microemulsions for ophthalmic administration | |
| MX2017009449A (es) | Inhibidor jak. | |
| HUE055369T2 (hu) | Gyógyászati készítmények cisztás fibrózis transzmembrán konduktancia regulátor kövzetítette betegségek kezelésére | |
| GB201500314D0 (en) | Pharmaceutical formulations for the treatment of pulmonary arterial hypertension | |
| MX385717B (es) | Regimen de dosificacion para el tratamiento de exacerbaciones agudas de enfermedad pulmonar obstructiva cronica. | |
| PH12014502107A1 (en) | Use of a pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease | |
| IL263516B (en) | A dosage form for vaporization and smoking | |
| DK4212152T3 (da) | Sacubitril-valsartan-doseringsregime til behandling af kronisk systolisk hjertesvigt | |
| DK3258938T3 (da) | Phenothiazinanaloger som mitokondrie terapeutiske midler | |
| EP3348648A4 (en) | VEHICLES FOR INTRA-CELLULAR RELEASE | |
| EP3344232A4 (en) | MICELLES FOR MUCOADHESIVE ACTIVE INFUSION | |
| ZA201708611B (en) | Pyrazole derivative, or pharmaceutically acceptable salt thereof | |
| LT3687567T (lt) | Anti-adrenomedulino rišiklis, skirtas panaudoti taikant ligos simptomų terapiją arba profilaktiką | |
| MX389563B (es) | Regimen de dosificacion para el tratamiento de exacerbaciones agudas de condiciones inflamatorias. | |
| EP4233950C0 (en) | NASAL ADMINISTRATION | |
| LT3601277T (lt) | Farmacinė vaisto forma | |
| EP3612231C0 (en) | DRUG DELIVERY SYSTEM | |
| CL2013002325A1 (es) | Compuestos derivados de 4-amino-2-butenamidas, inhibidores de catepsina c; composicion farmaceutica que los comprende; procedimiento de preparacion de la composicion farmaceutica; uso del compuesto en el tratamiento de enfermedad pulmonar obstructiva cronica. | |
| PH12017501955A1 (en) | Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer`s disease | |
| PL3368015T3 (pl) | Dostarczanie niesteroidowego leku przeciwzapalnego o przedłużonym uwalnianiu | |
| EP3375456A4 (en) | TOPICALLY APPLIED MEDICINE WITH DELAYED RELEASE | |
| CL2017000026A1 (es) | Formas de dosificación farmacéutica | |
| IT201700011337A1 (it) | Compressa multistrato per la somministrazione di magnesio | |
| LT3244889T (lt) | Farmacinė kompozicija, skirta mikozės gydymui |